HLS.TO
HLS Therapeutics Inc. [HLS.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
HLS.TO Stock Summary
Top 10 Correlated ETFs
HLS.TO
Top 10 Correlated Stocks
HLS.TO
In the News
HLS.TO Financial details
Company Rating
Neutral
Market Cap
165.03M
Income
-27.53M
Revenue
63.07M
Book val./share
-
Cash/share
-
Dividend
0.1
Dividend %
3.35%
Employees
91
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-3.37
Forward P/E
-
PEG
4.92
P/S
1.52
P/B
0.95
P/C
-
P/FCF
6.18
Quick Ratio
1.29
Current Ratio
1.72
Debt / Equity
0.9
LT Debt / Equity
0.84
-
-
EPS (TTM)
-0.68
EPS next Y
-
EPS next Q
-
EPS this Y
16.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
4.87%
Revenue last 5Y
3.09%
Revenue Q/Q
-1.08%
EPS Q/Q
-
-
-
-
-
SMA20
25%
SMA50
25%
SMA100
25%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-25%
ROC
-0.07%
Gross Margin
89%
Oper. Margin
-21%
Profit Margin
-45%
Payout
-13%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.34-7.12
52W High
-29.29%
52W Low
+65%
RSI
65
Rel Volume
0.02
Avg Volume
9.56K
Volume
200
Perf Week
-3.51%
Perf Month
17.58%
Perf Quarter
4.21%
Perf Half Y
1.85%
-
-
-
-
Beta
1.138
-
-
Volatility
0.09%, 0.49%
Prev Close
0.61%
Price
4.95
Change
1.02%
HLS.TO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.86 | 1.77 | 1.86 | 1.9 | 1.95 | |
| Net income per share | -0.67 | -0.48 | -0.41 | -0.73 | -0.85 | |
| Operating cash flow per share | 0.9 | 0.29 | 0.51 | 0.52 | 0.49 | |
| Free cash flow per share | 0.82 | -1.11 | 0.37 | 0.21 | 0.48 | |
| Cash per share | 1.61 | 0.65 | 0.66 | 0.64 | 0.68 | |
| Book value per share | 6.11 | 5.34 | 4.99 | 3.88 | 3.03 | |
| Tangible book value per share | -2.53 | -2.65 | -2.13 | -2.16 | -2 | |
| Share holders equity per share | 6.11 | 5.34 | 4.99 | 3.88 | 3.03 | |
| Interest debt per share | 3.45 | 3.58 | 3.25 | 3.24 | 2.99 | |
| Market cap | 572.62M | 448.23M | 378.8M | 234.48M | 96.08M | |
| Enterprise value | 618.65M | 534.74M | 455.19M | 311.1M | 161.75M | |
| P/E ratio | -29.29 | -29.24 | -28.88 | -9.94 | -3.49 | |
| Price to sales ratio | 10.57 | 7.99 | 6.31 | 3.81 | 1.52 | |
| POCF ratio | 21.68 | 47.97 | 23.06 | 13.84 | 6.09 | |
| PFCF ratio | 24.01 | -12.69 | 31.78 | 34.51 | 6.16 | |
| P/B Ratio | 3.21 | 2.65 | 2.36 | 1.87 | 0.98 | |
| PTB ratio | 3.21 | 2.65 | 2.36 | 1.87 | 0.98 | |
| EV to sales | 11.42 | 9.53 | 7.59 | 5.06 | 2.56 | |
| Enterprise value over EBITDA | 21.73 | 24.38 | 18.95 | 14.84 | 7.37 | |
| EV to operating cash flow | 23.43 | 57.23 | 27.71 | 18.36 | 10.24 | |
| EV to free cash flow | 25.94 | -15.13 | 38.19 | 45.79 | 10.37 | |
| Earnings yield | -0.03 | -0.03 | -0.03 | -0.1 | -0.29 | |
| Free cash flow yield | 0.04 | -0.08 | 0.03 | 0.03 | 0.16 | |
| Debt to equity | 0.52 | 0.63 | 0.61 | 0.78 | 0.9 | |
| Debt to assets | 0.29 | 0.35 | 0.35 | 0.4 | 0.42 | |
| Net debt to EBITDA | 1.62 | 3.94 | 3.18 | 3.66 | 2.99 | |
| Current ratio | 1.34 | 1.29 | 1.58 | 1.42 | 1.65 | |
| Interest coverage | -0.53 | -1.78 | -0.9 | -1.84 | -1.14 | |
| Income quality | -1.35 | -0.61 | -1.25 | -0.72 | -0.57 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Payout ratio | -0.22 | -0.31 | -0.39 | -0.21 | -0.09 | |
| Sales general and administrative to revenue | 0.33 | 0.33 | 0.29 | 0.29 | 0.13 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.79 | 0.83 | 0.83 | 0.81 | 0.78 | |
| Capex to operating cash flow | -0.1 | -4.78 | -0.27 | -0.6 | -0.01 | |
| Capex to revenue | -0.05 | -0.8 | -0.08 | -0.17 | 0 | |
| Capex to depreciation | -0.08 | -1.35 | -0.15 | -0.29 | -0.01 | |
| Stock based compensation to revenue | 0.07 | 0.05 | 0.04 | 0.05 | -0.01 | |
| Graham number | 9.59 | 7.62 | 6.77 | 7.98 | 7.62 | |
| ROIC | -0.01 | -0.04 | -0.03 | -0.06 | -0.05 | |
| Return on tangible assets | -0.29 | -0.3 | -0.28 | -0.51 | -0.59 | |
| Graham Net | -2.89 | -3.13 | -2.51 | -2.56 | -2.37 | |
| Working capital | 15.96M | 10.27M | 16.08M | 13.18M | 17.41M | |
| Tangible asset value | -73.85M | -84.16M | -68.45M | -69.7M | -64.65M | |
| Net current asset value | -78.37M | -88.75M | -71.42M | -71.96M | -67.27M | |
| Invested capital | 0.52 | 0.63 | 0.61 | 0.78 | 0.9 | |
| Average receivables | 14.68M | 12.18M | 12M | 11.35M | 10.94M | |
| Average payables | 12.94M | 13.84M | 11.77M | 10.45M | 12.85M | |
| Average inventory | 1.78M | 6.34M | 9.78M | 8.91M | 9.22M | |
| Days sales outstanding | 79.91 | 81.3 | 70.01 | 66.47 | 61.88 | |
| Days payables outstanding | 2.54K | 1.43K | 856.08 | 849.37 | 675.37 | |
| Days of inventory on hand | 388.24 | 1.07K | 820.15 | 652.32 | 456.44 | |
| Receivables turnover | 4.57 | 4.49 | 5.21 | 5.49 | 5.9 | |
| Payables turnover | 0.14 | 0.25 | 0.43 | 0.43 | 0.54 | |
| Inventory turnover | 0.94 | 0.34 | 0.45 | 0.56 | 0.8 | |
| ROE | -0.11 | -0.09 | -0.08 | -0.19 | -0.28 | |
| Capex per share | -0.09 | -1.41 | -0.14 | -0.31 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.48 | 0.46 | 0.51 | 0.5 | 0 | |
| Net income per share | -0.2 | -0.18 | -0.29 | -0.21 | 0 | |
| Operating cash flow per share | 0.11 | 0.12 | 0.08 | 0.17 | 0 | |
| Free cash flow per share | 0.11 | 0.12 | 0.08 | 0.17 | 0 | |
| Cash per share | 0.64 | 0.66 | 0.65 | 0.68 | 0 | |
| Book value per share | 3.87 | 3.67 | 3.45 | 3.16 | 0 | |
| Tangible book value per share | -2.15 | -2.1 | -2.08 | -2.08 | 0 | |
| Share holders equity per share | 3.87 | 3.67 | 3.45 | 3.16 | 0 | |
| Interest debt per share | 3.07 | 3 | 2.97 | 2.88 | 0 | |
| Market cap | 234.9M | 150.79M | 140.61M | 117.9M | 0 | |
| Enterprise value | 311.52M | 224.77M | 213.76M | 186.82M | 65.67M | |
| P/E ratio | -9.13 | -6.51 | -3.73 | -4.27 | 0 | |
| Price to sales ratio | 14.99 | 10.22 | 8.57 | 7.35 | 0 | |
| POCF ratio | 66.71 | 37.51 | 52.7 | 21.97 | 0 | |
| PFCF ratio | 67.09 | 37.51 | 53.24 | 22.13 | 0 | |
| P/B Ratio | 1.87 | 1.27 | 1.26 | 1.16 | 0 | |
| PTB ratio | 1.87 | 1.27 | 1.26 | 1.16 | 0 | |
| EV to sales | 19.87 | 15.23 | 13.02 | 11.65 | 4.14 | |
| Enterprise value over EBITDA | 67.58 | 43.6 | 39.69 | 35.62 | 10.67 | |
| EV to operating cash flow | 88.48 | 55.91 | 80.12 | 34.81 | 17.59 | |
| EV to free cash flow | 88.98 | 55.91 | 80.94 | 35.07 | 17.65 | |
| Earnings yield | -0.03 | -0.04 | -0.07 | -0.06 | 0 | |
| Free cash flow yield | 0.01 | 0.03 | 0.02 | 0.05 | 0 | |
| Debt to equity | 0.78 | 0.8 | 0.84 | 0.89 | 0.9 | |
| Debt to assets | 0.4 | 0.41 | 0.41 | 0.42 | 0.42 | |
| Net debt to EBITDA | 16.62 | 14.35 | 13.58 | 13.14 | 10.67 | |
| Current ratio | 1.42 | 1.48 | 1.45 | 1.72 | 1.65 | |
| Interest coverage | -2.09 | -1.65 | -1.54 | -1.29 | -0.34 | |
| Income quality | -0.55 | -0.69 | -0.28 | -0.78 | -0.69 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Payout ratio | -0.19 | -0.2 | -0.13 | 0 | 0 | |
| Sales general and administrative to revenue | 0.28 | 0.23 | 0.24 | 0.25 | 0.08 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.81 | 0.8 | 0.79 | 0.78 | 0.78 | |
| Capex to operating cash flow | -0.01 | 0 | -0.01 | -0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.05 | 0 | 0.01 | 0 | -0.04 | |
| Graham number | 4.16 | 3.85 | 4.76 | 3.9 | 0 | |
| ROIC | -0.02 | -0.01 | -0.01 | -0.01 | 0 | |
| Return on tangible assets | -0.14 | -0.12 | -0.2 | -0.15 | -0.12 | |
| Graham Net | -2.56 | -2.51 | -2.49 | -2.46 | 0 | |
| Working capital | 13.18M | 14.65M | 14.13M | 18.15M | 17.41M | |
| Tangible asset value | -69.7M | -68.09M | -67.37M | -67.07M | -64.65M | |
| Net current asset value | -71.96M | -70.22M | -69.72M | -69.97M | -67.27M | |
| Invested capital | 0.78 | 0.8 | 0.84 | 0.89 | 0.9 | |
| Average receivables | 10.76M | 10.67M | 11.11M | 11.39M | 10.71M | |
| Average payables | 11.85M | 12.41M | 13.08M | 13.47M | 14.06M | |
| Average inventory | 9.49M | 9.81M | 10.34M | 9.36M | 9.14M | |
| Days sales outstanding | 64.27 | 61.93 | 66.16 | 60.15 | 60.67 | |
| Days payables outstanding | 687.67 | 825.08 | 654.61 | 674.33 | 501.24 | |
| Days of inventory on hand | 528.13 | 667.46 | 504.7 | 421.27 | 338.75 | |
| Receivables turnover | 1.4 | 1.45 | 1.36 | 1.5 | 1.48 | |
| Payables turnover | 0.13 | 0.11 | 0.14 | 0.13 | 0.18 | |
| Inventory turnover | 0.17 | 0.13 | 0.18 | 0.21 | 0.27 | |
| ROE | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
HLS.TO Frequently Asked Questions
What is HLS Therapeutics Inc. stock symbol ?
HLS Therapeutics Inc. is a CA stock , located in Etobicoke of On and trading under the symbol HLS.TO
What is HLS Therapeutics Inc. stock quote today ?
HLS Therapeutics Inc. stock price is $4.95 today.
Is HLS Therapeutics Inc. stock public?
Yes, HLS Therapeutics Inc. is a publicly traded company.
Company Profile
- Volume Average 9.56K
- Market Capitalization 165.03M
- Employee 91
- CEO Mr. Craig Stuart Millian M.B.A.
- Headquarters Etobicoke,ON,CA
- IPO Date 2018-03-14
-
Website
https://www.hlstherapeutics.com 
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
